Management ChangeJul 7, 2026, 04:07 PM
Vor Biopharma Appoints David Zaccardelli to Board; Andrew Levin Resigns
AI Summary
Vor Biopharma Inc. announced a change to its Board of Directors. Andrew Levin, M.D., Ph.D. resigned from his position, effective July 6, 2026. Following this, David Zaccardelli, Pharm.D. was appointed to the Board as an independent Class II director, effective July 7, 2026. Dr. Zaccardelli brings extensive experience from previous CEO roles at public pharmaceutical companies and will receive standard non-employee director compensation.
Key Highlights
- Andrew Levin, M.D., Ph.D. resigned from Vor Biopharma's Board of Directors, effective July 6, 2026.
- David Zaccardelli, Pharm.D. was appointed to the Board as an independent Class II director, effective July 7, 2026.
- Dr. Zaccardelli will serve until the Company's 2029 annual meeting of stockholders.
- Dr. Zaccardelli previously served as CEO of Verona Pharma plc and Dova Pharmaceuticals, Inc.
- He will receive an annual cash retainer fee of $40,000 for his service.
- Dr. Zaccardelli will receive an initial stock option grant for up to 68,000 shares or $700,000 fair value.
- He will be eligible for an annual stock option grant for up to 34,000 shares or $350,000 fair value.
Price Impact
More from VOR